Penumbra to be Acquired by Boston Scientific for $14.5 Billion in Cash and Stock

summarizeResumen

Penumbra has entered into a definitive merger agreement to be acquired by Boston Scientific, a major development that fundamentally alters the investment thesis for Penumbra shareholders. The acquisition price of $374 per share represents a significant premium over Penumbra's current stock price of $351.00 and its 52-week high of $325.025, indicating strong value for shareholders. The consideration structure, offering a mix of cash and Boston Scientific stock, provides flexibility while ensuring a substantial immediate return. This transaction is a major strategic move for both companies, with Penumbra's portfolio expanding Boston Scientific's presence in fast-growing vascular segments. The deal is subject to customary closing conditions, including shareholder and regulatory approvals, with an expected completion in 2026.

check_boxEventos clave

• Definitive Merger Agreement

  Penumbra, Inc. has entered into an Agreement and Plan of Merger to be acquired by Boston Scientific Corporation.

• Acquisition Price and Premium

  The transaction values Penumbra at $374 per share, representing a significant premium to the current stock price of $351.00 and the 52-week high of $325.025.

• Consideration Structure

  Shareholders can elect to receive $374 in cash or 3.8721 shares of Boston Scientific common stock, subject to proration, resulting in approximately 73% cash and 27% stock.

• Enterprise Value

  The total enterprise value of the acquisition is approximately $14.5 billion.

auto_awesomeAnalisis

Penumbra has entered into a definitive merger agreement to be acquired by Boston Scientific, a major development that fundamentally alters the investment thesis for Penumbra shareholders. The acquisition price of $374 per share represents a significant premium over Penumbra's current stock price of $351.00 and its 52-week high of $325.025, indicating strong value for shareholders. The consideration structure, offering a mix of cash and Boston Scientific stock, provides flexibility while ensuring a substantial immediate return. This transaction is a major strategic move for both companies, with Penumbra's portfolio expanding Boston Scientific's presence in fast-growing vascular segments. The deal is subject to customary closing conditions, including shareholder and regulatory approvals, with an expected completion in 2026.